An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.


China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion
ASX Shares Slide After ASIC Imposes A$150 Million Capital Requirement
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny
Indonesia–U.S. Tariff Talks Near Completion as Both Sides Push for Year-End Deal
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Asian Stocks Rally as Tech Rebounds, China Lags on Nvidia Competition Concerns
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
Oil Prices Rebound in Asia as Venezuela Sanctions Risks Offset Ukraine Peace Hopes
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies
Gold Prices Dip as Markets Absorb Dovish Fed Outlook; Silver Eases After Record High 



